Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Non-Current Assets: 2022-2024

Historic Non-Current Assets for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to $83.4 million.

  • Axsome Therapeutics' Non-Current Assets rose 26.19% to $103.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.9 million, marking a year-over-year increase of 26.19%. This contributed to the annual value of $83.4 million for FY2024, which is 0.64% down from last year.
  • According to the latest figures from FY2024, Axsome Therapeutics' Non-Current Assets is $83.4 million, which was down 0.64% from $84.0 million recorded in FY2023.
  • In the past 5 years, Axsome Therapeutics' Non-Current Assets registered a high of $85.8 million during FY2022, and its lowest value of $83.4 million during FY2024.
  • In the last 3 years, Axsome Therapeutics' Non-Current Assets had a median value of $84.0 million in 2023 and averaged $84.4 million.
  • Data for Axsome Therapeutics' Non-Current Assets shows a maximum YoY fell of 2.17% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Axsome Therapeutics' Non-Current Assets stood at $85.8 million in 2022, then dropped by 2.17% to $84.0 million in 2023, then decreased by 0.64% to $83.4 million in 2024.